Alexandros Tsimpolis

Mr. Alexandros Tsimpolis

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2024 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
MKMaria Kokkali
Maria Kokkali
KKKanelina Karali
Kanelina Karali
ETEvangelia Thanou
Evangelia Thanou
MPMaria Anna Papadopoulou
Maria Anna Papadopoulou
IZIoanna Zota
Ioanna Zota
Ioannis CharalampopoulosIoannis Charalampopoulos
Ioannis Charalampopoulos
Alzheimer’s Disease (AD) is an incurable and debilitating progressive, neurodegenerative disorder which is the leading cause of dementia worldwide. Neuropathologically, AD is characterized by the accumulation of Aβ amyloid plaques in the microenvironment of brain cells and neurovascular walls, chronic neuroinflammation, resulting in neuronal and synaptic loss, myelin and axonal failure, as well as significant reduction in adult hippocampal neurogenesis. The hippocampal formation is particularly vulnerable to this degenerative process, due to early dysfunction of the cholinergic circuit. Neurotrophic factors consist major regulatory molecules and their decline in AD is considered as an important cause of disease onset and progression. Novel pharmacological approaches are targeting the downstream pathways controlled by neurotrophins, such as nerve growth factor (NGF) receptors, TrkA and p75NTR, which enhance hippocampal neurogenic capacity and neuroprotective mechanisms, and potentially counteract the neurotoxic effects of amyloid deposition. BNN27 is a non-toxic, newly developed 17-spiro-steroid analog, penetrating the blood-brain-barrier (BBB) and mimicking the neuroprotective effects of NGF, acting as selective activator of its receptors, both TrkA and p75NTR, thus promoting survival of various neuronal cell types. Our present research aims at determining whether and which aspects of the AD-related pathology, BNN27 is able to alleviate, exploring the cellular and molecular AD components and link these changes with improvements in the cognitive performance of an animal AD model, the 5xFAD mice. Our results clearly indicate that BNN27 administration significantly reduced amyloid-β load in whole brain of the animals, enhanced adult hippocampal neurogenesis, restored cholinergic function and synaptogenesis, reducing inflammatory activation and leading to significant restoration of cognitive functions. BNN27 may represent a new lead multimodal molecule with neuroprotective, neurogenic and anti-neuroinflammatory actions for developing druggable anti-Alzheimeric agents. Proteomics data are available via ProteomeXchange with the identifier PXD044699.

16 September 2025 in Polymers
Verified
Journal Article
Open access
PDF file
Ermis P. ChristodoulouErmis P. Christodoulou
Ermis P. Christodoulou
ATAlexandros Tsimpolis
Alexandros Tsimpolis
KTKostas Theodorakis
Kostas Theodorakis
SAStyliani Axypolitou
Styliani Axypolitou
Ioannis TsamesidisIoannis Tsamesidis
Ioannis Tsamesidis
Dimitrios BikiarisDimitrios Bikiaris
Dimitrios Bikiaris
Background/Objectives: Biodegradable and pH-responsive nanocarriers using zwitterionic moieties represent a promising avenue for targeted delivery of chemotherapeutics. The present study addresses this by developing zwitterionic nanoparticles based on polylactic acid/poly(ethylene adipate) (PLA/PEAd) copolymers grafted with SBMA, designed to combine acid-triggered drug release with stealth-like biocompatibility. Methods: A series of polylactic acid/poly(ethylene adipate) (PLA/PEAd) copolymers with varying compositions (95/5, 90/10, and 75/25 w/w) were synthesized via ring-opening polymerization, followed by controlled radical grafting of the zwitterionic monomer [2-(Methacryloyloxy)ethyl]dimethyl-(3-sulfopropyl)ammonium hydroxide (SBMA), which was then successfully grafted upon their backbone. The resulting zwittenionic copolymers were thoroughly characterized for their structural and physicochemical properties, displaying tunable molecular weights of 3200–4900 g/mol, enhanced hydrophilicity and controlled degradation, with mass loss ranging from 8% to 83% over 30 days, depending on PEAd content and pH. Paclitaxel-loaded nanoparticles of spherical shape with sizes ranging from 220 to 565 nm were then fabricated. Drug release was pH-dependent with significantly higher release at pH 5.0 (up to ~79% for PLAPEAd7525-SBMA) compared to pH 7.4 (~18–35%). Hemolysis assays demonstrated excellent hemocompatibility, and cytotoxicity studies showed strong anticancer activity (>80% cell death in MDA-MB-231) with lower toxicity toward iMEFs, especially for PEAd-rich formulations. Conclusions: Our findings underline the potential of SBMA-functionalized PLA/PEAd nanoparticles as effective nano-carriers for tumor-targeted chemotherapy.

18 September 2022 in Biomolecules
Verified
Journal Article
Open access
PDF file
ATAlexandros Tsimpolis
Alexandros Tsimpolis
MKMaria Kokkali
Maria Kokkali
ALAris Logothetis
Aris Logothetis
Konstantinos KalafatakisKonstantinos Kalafatakis
Konstantinos Kalafatakis
Ioannis CharalampopoulosIoannis Charalampopoulos
Ioannis Charalampopoulos
Novel research studies indicate multivarious interactions of glucocorticoid hormones (GCs) with the brain-derived neurotrophic factor (BDNF), regulating important aspects of neuronal cell physiology. While there is recent evidence of the chronic effects of GC stimulation on BDNF levels, as well as of the role of BDNF stimulation in the type of genomic effects following activation of GC-sensitive receptors, no data exist concerning the acute effects of GC stimulation on BDNF/TrkB gene expression. To address this question, we conducted a chrono-pharmacological study on rodent glial cells, astrocytes, which express the BDNF receptor, TrkB, following corticosterone administration. mRNA levels of BDNF and TrkB were estimated 1, 6, 12 and 24 h post-treatment. Selective inhibitors for GC-sensitive receptors and TrkB were used to decipher the molecular pathways of the effects observed. Our data support a biphasic response of BDNF expression after corticosterone stimulation. This response is characterized by a rapid TrkB phosphorylation-dependent upregulation of BDNF mRNA within the first hour, followed by a glucocorticoid receptor (GR)-dependent downregulation of BDNF mRNA, evident at 6, 12 and 24 h, with a direct impact on the protein levels of mature BDNF. Finally, a second pulse of corticosterone administration 1 h prior to the 6, 12 or 24 h timepoints normalized BDNF expression for the corresponding timepoint (i.e., mRNA levels became indifferent from baseline). These results present for the first time a biphasic regulation of the neurotrophin system based on glucocorticoid rhythmicity, further indicating complex trophic responses to temporal hormonal mechanisms in the brain microenvironment.

28 February 2024 in Research Square
Verified
Preprint
Open access
PDF file
Ioannis CharalampopoulosIoannis Charalampopoulos
Ioannis Charalampopoulos
MKMaria Kokkali
Maria Kokkali
KKKanelina Karali
Kanelina Karali
ETEvangelia Thanou
Evangelia Thanou
MPMaria Papadopoulou
Maria Papadopoulou
AGAchille Gravanis
Achille Gravanis
Alzheimer’s Disease (AD) is an incurable and debilitating progressive, neurodegenerative disorder which is the leading cause of dementia worldwide. Neuropathologically, AD is characterized by the accumulation of Aβ amyloid plaques in the microenvironment of brain cells and neurovascular walls, chronic neuroinflammation, resulting in neuronal and synaptic loss, myelin and axonal failure, as well as significant reduction in adult hippocampal neurogenesis. The hippocampal formation is particularly vulnerable to this degenerative process, due to early dysfunction of the cholinergic circuit. Neurotrophic factors consist major regulatory molecules and their decline in AD is considered as an important cause of disease onset and progression. Novel pharmacological approaches are targeting the downstream pathways controlled by neurotrophins, such as nerve growth factor (NGF) receptors, TrkA and p75NTR, which enhance hippocampal neurogenic capacity and neuroprotective mechanisms, and potentially counteract the neurotoxic effects of amyloid deposition. BNN27 is a non-toxic, newly developed 17-spiro-steroid analog, penetrating the blood-brain-barrier (BBB) and mimicking the neuroprotective effects of NGF, acting as selective activator of its receptors, both TrkA and p75NTR, thus promoting survival of various neuronal cell types. Our present research aims at determining whether and which aspects of the AD-related pathology, BNN27 is able to alleviate, exploring the cellular and molecular AD components and link these changes with improvements in the cognitive performance of an animal AD model, the 5xFAD mice. Our results clearly indicate that BNN27 administration significantly reduced amyloid-β load in whole brain of the animals, enhanced adult hippocampal neurogenesis, restored cholinergic function and synaptogenesis, reducing inflammatory activation and leading to significant restoration of cognitive functions. BNN27 may represent a new lead multimodal molecule with neuroprotective, neurogenic and anti-neuroinflammatory actions for developing druggable anti-Alzheimeric agents. Proteomics data are available via ProteomeXchange with the identifier PXD044699.

14 October 2026 in Biomolecules
Verified
Journal Article
Open access
PDF file
DSDimitris Spyridakos
Dimitris Spyridakos
IZIoannis Zyganitidis
Ioannis Zyganitidis
SPSofia Petsangouraki
Sofia Petsangouraki
CKChrystalla Konstantinou
Chrystalla Konstantinou
ATAlexandros Tsimpolis
Alexandros Tsimpolis
 Domna  Karagogeos Domna Karagogeos
Domna Karagogeos
Excitotoxicity mediated by the α-amino-3-hydroxy-5-methyl-4 isoxazolepropionic acid receptor (AMPAR) is a major contributor to neuronal degeneration and inflammation in various neurological disorders. The endocannabinoid system (ECS), specifically through the endocannabinoid 2-arachidonoylglycerol (2-AG), exerts neuroprotective and anti-inflammatory effects, but these actions are limited by enzymatic degradation of 2-AG by monoacylglycerol lipase (MAGL) and α/β-hydrolase domain-containing protein 6 (ABHD6). In the present study we investigated the effects of AM11920, a dual MAGL/ABHD6 inhibitor, in a mouse model of AMPA-induced cortical excitotoxicity and in primary cultures of microglia, neurons, and oligodendrocyte precursor cells (OPCs). Intraperitoneal administration (i.p.) of AM11920 reduced microglial and astrocytic reactivity, attenuated neuronal loss, and increased the density of mature oligodendrocytes at the lesion site in vivo. Importantly, chronic administration of AM11920 in vivo did not affect cannabinoid receptor type 1 (CB1R) protein expression. In vitro, AM11920 suppressed microglial activation by reducing CD68 expression and attenuated interleukin-6 (IL-6) expression, while also protecting primary neurons and OPCs from AMPA-induced cell death via a CB1R-dependent mechanism. Collectively, these findings demonstrate that enhancing 2-AG signaling through dual MAGL/ABHD6 blockade provides neuroprotective and immunomodulatory effects and represents a promising therapeutic strategy against excitotoxic-induced neurodegeneration.